EA200000270A1 - КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Info

Publication number
EA200000270A1
EA200000270A1 EA200000270A EA200000270A EA200000270A1 EA 200000270 A1 EA200000270 A1 EA 200000270A1 EA 200000270 A EA200000270 A EA 200000270A EA 200000270 A EA200000270 A EA 200000270A EA 200000270 A1 EA200000270 A1 EA 200000270A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
interferon
application
genotherapy
compositions
Prior art date
Application number
EA200000270A
Other languages
English (en)
Other versions
EA003256B1 (ru
Inventor
Джеймс Г. Барсум
Ксиао-Квианг Квин
Original Assignee
Байоджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен, Инк. filed Critical Байоджен, Инк.
Publication of EA200000270A1 publication Critical patent/EA200000270A1/ru
Publication of EA003256B1 publication Critical patent/EA003256B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к способам и фармацевтическим композициям, предназначенным для модификации in situ клеток млекопитающего-реципиента при помощи ДНК, кодирующей секретируемый белок, такой как интерферон человека. Эти способы включают получение системы экспрессии секретируемого белка in vivo или ex vivo и введение этой экспрессирующей системы млекопитающему-реципиенту. Эта экспрессирующая система и способы ее применения обеспечивают эффективную локализованную и системную доставку интерферонов in situ.Отчет о международном поиске был опубликован 1999.05.06.
EA200000270A 1997-08-29 1998-08-25 СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ IN VIVO ПРИ ПОМОЩИ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ β-ИНТЕРФЕРОН EA003256B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (2)

Publication Number Publication Date
EA200000270A1 true EA200000270A1 (ru) 2000-10-30
EA003256B1 EA003256B1 (ru) 2003-02-27

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000270A EA003256B1 (ru) 1997-08-29 1998-08-25 СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ IN VIVO ПРИ ПОМОЩИ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ β-ИНТЕРФЕРОН

Country Status (25)

Country Link
EP (1) EP1007717B8 (ru)
JP (3) JP4124565B2 (ru)
KR (1) KR100699285B1 (ru)
CN (1) CN100342019C (ru)
AT (1) ATE316145T1 (ru)
AU (1) AU740428B2 (ru)
BR (1) BR9812138A (ru)
CA (1) CA2300480C (ru)
CY (1) CY1105029T1 (ru)
CZ (2) CZ299095B6 (ru)
DE (1) DE69833264T2 (ru)
DK (1) DK1007717T3 (ru)
EA (1) EA003256B1 (ru)
EE (1) EE04873B1 (ru)
ES (1) ES2257817T3 (ru)
HK (1) HK1029599A1 (ru)
HU (1) HU224422B1 (ru)
IL (2) IL134593A0 (ru)
IS (1) IS2318B (ru)
NO (1) NO20000990L (ru)
NZ (1) NZ503401A (ru)
PT (1) PT1007717E (ru)
SK (1) SK286821B6 (ru)
TR (1) TR200000532T2 (ru)
WO (1) WO1999010516A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363676B1 (en) 2001-01-22 2007-03-28 Biogen Idec MA Inc. Method of enhancing delivery of a therapeutic nucleic acid
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD35Z (ru) * 2008-12-02 2010-01-31 Василе ЖОВМИР Метод оценки риска развития неинвазивной карциномы in situ молочной железы
MD24Z (ru) * 2008-12-02 2010-01-31 Василе ЖОВМИР Метод дифференциального лечения неинвазивной карциномы молочной железы
MD36Z (ru) * 2008-12-02 2010-01-31 Василе ЖОВМИР Метод дифференциального лечения неинвазивной дуктальной карциномы in situ молочной железы
MD23Z (ru) * 2008-12-02 2010-01-31 Василе ЖОВМИР Метод дифференциального лечения неинвазивной лобулярной карциномы in situ молочной железы
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
US20190125804A1 (en) * 2016-06-15 2019-05-02 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
CA3142425A1 (en) * 2019-06-01 2020-12-10 Sivec Biotechnologies, Llc A bacterial platform for delivery of gene-editing systems to eukaryotic cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
EP1369487A3 (en) * 1994-08-16 2004-04-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
HUP0002913A3 (en) 2003-08-28
CY1105029T1 (el) 2010-03-03
ES2257817T3 (es) 2006-08-01
CN100342019C (zh) 2007-10-10
HUP0002913A2 (hu) 2000-12-28
EP1007717B1 (en) 2006-01-18
EE200000102A (et) 2000-12-15
PT1007717E (pt) 2006-06-30
IS2318B (is) 2007-11-15
CA2300480C (en) 2010-01-05
HK1029599A1 (en) 2001-04-06
DE69833264T2 (de) 2006-09-28
JP2004155786A (ja) 2004-06-03
JP3953458B2 (ja) 2007-08-08
AU9205198A (en) 1999-03-16
JP4124565B2 (ja) 2008-07-23
NZ503401A (en) 2003-01-31
SK286821B6 (sk) 2009-06-05
WO1999010516A2 (en) 1999-03-04
CZ299095B6 (cs) 2008-04-23
IS5374A (is) 2000-02-11
CZ297314B6 (cs) 2006-11-15
CN1271391A (zh) 2000-10-25
DK1007717T3 (da) 2006-05-29
CZ2000733A3 (cs) 2000-06-14
CA2300480A1 (en) 1999-03-04
TR200000532T2 (tr) 2000-11-21
JP2005225888A (ja) 2005-08-25
EA003256B1 (ru) 2003-02-27
KR100699285B1 (ko) 2007-03-26
KR20010023511A (ko) 2001-03-26
HU224422B1 (hu) 2005-08-29
IL134593A (en) 2007-06-17
AU740428B2 (en) 2001-11-01
NO20000990L (no) 2000-05-02
SK2482000A3 (en) 2000-08-14
WO1999010516A3 (en) 1999-05-06
EP1007717B8 (en) 2006-05-03
DE69833264D1 (de) 2006-04-06
ATE316145T1 (de) 2006-02-15
EP1007717A2 (en) 2000-06-14
JP4219335B2 (ja) 2009-02-04
JP2001514010A (ja) 2001-09-11
BR9812138A (pt) 2000-07-18
IL134593A0 (en) 2001-04-30
EE04873B1 (et) 2007-08-15
NO20000990D0 (no) 2000-02-28

Similar Documents

Publication Publication Date Title
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
ATE169959T1 (de) Anthrax-toxin-fusionsproteine und deren verwendungen
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
CY1105029T1 (el) Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα
DE69841015D1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
ATE353964T1 (de) Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
DE60031418D1 (de) 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen
DE60140559D1 (de) 32144, eine humane fettsäureamid-hydrolase und deren verwendungen
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
DE69734596D1 (de) "smoothened" proteine aus wirbeltieren
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
DE60124910D1 (de) Menschliche twik-8 moleküle und ihre verwendung
WO2002051992A3 (en) 21163, a novel human prolyl oligopeptidase and uses therefor
WO2002018577A3 (en) 48921, a novel human gtp releasing factor and uses therefor

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU